DOI:
10.1055/s-00000071
Seminars in Neurology
LinksSchließen
Referenz
Miller T, Habek M, Coles AJ , et al.
Analysis of data from RRMS alemtuzumab-treated patients in the clinical program to evaluate incidence rates of malignancy.
Poster presented at: 30th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; September 10–13, 2014; Boston, MA
Für die Inhalte der Internetseiten anderer Anbieter übernehmen wir keine Verantwortung.